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Abstract
Background and aims
The effect of smoking on the risk of developing inflammatory bowel diseases (IBD) may be
heterogeneous across ethnicity and geography. Although trends in smoking for the general
population are well described, it is unknown whether these can be extrapolated to the IBD
cohort. Smoking prevalence trends specific to the global IBD cohort over time have not been
previously reported. This is a systematic review of smoking prevalence specific to the IBD
cohort across geography.
Methods
A systematic literature search was conducted on Medline and Embase from January 1st
1946 to April 5th 2018 to identify population-based studies assessing the prevalence of
smoking at diagnosis in inception cohorts of Crohn’s disease(CD) or ulcerative colitis(UC).
Studies that did not report smoking data from time of diagnosis or the year of IBD diagnosis
were excluded. Prevalence of smoking in IBD was stratified by geography and across time.
Results
We identified 56 studies that were eligible for inclusion. Smoking prevalence data at diagno-
sis of CD and UC was collected from twenty and twenty-five countries respectively. Never-
smokers in the newly diagnosed CD population in the West has increased over the last two
decades, especially in the United Kingdom and Sweden; +26.6% and +11.2% respectively.
Never-smokers at CD diagnosis in newly industrialised nations have decreased over the
1990s and 2000s; China (-19.36%). Never-smokers at UC diagnosis also decreased in
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China; -15.4%. The former-smoker population at UC diagnosis in China is expanding; 11%
(1990–2006) to 34%(2011–2013).
Conclusion
There has been a reduction in the prevalence of smoking in the IBD cohort in the West. This
is not consistent globally. Although, smoking prevalence has decreased in the general popu-
lation of newly industrialised nations, this remains an important risk factor with longer term
outcomes awaiting translation in both UC and CD.
Introduction
Our group has extensively reported that inflammatory bowel diseases (IBD) have become a
global challenge in the 21st century.[1–5] The rapidly accelerating incidence of both Crohn’s
disease (CD) and ulcerative colitis (UC) in the newly industrialized countries in the East mir-
rors epidemiological patterns of IBD in the West more than 75 years ago.[2] The evolving epi-
demiology of IBD is thought to be associated with the industrialisation of society. The rise of
IBD incidence in newly industrialised nations combined with reports of comparable rates of
IBD in migrant and native populations in the West[6] support the theory that environmental
triggers and Western lifestyle have an integral role in the pathogenesis of IBD. [3,4]
The dichotomous relationship between smoking and the development of IBD has been the
subject of intense scrutiny and is a complex interplay of genetics, immunology and environ-
ment. In the West, smoking has been consistently reported as a risk factor for developing CD
and adversely affects disease course[7–9], whereas former smokers and non-smokers are at
increased risk of developing UC in comparison to current smokers.[10,11] In contrast, studies
in non-Western populations have been unable to replicate this association between CD and
smoking.[12] The interaction between smoking and the NOD-2 gene and their effect on the
risk of CD has been postulated to be specific to the 1007 fs mutation and a negative association
between NOD-2 mutation and smoking could be explained by their inverse relationship.[13]
An understanding of global smoking prevalence trends specific to the IBD cohort is
required as the foundation for further investigation of the heterogeneous influence of this risk
factor in IBD pathogenesis and disease course across different regions. In addition, this is
increasingly important in light of the identification of smoking as a key risk factor for non-
response to anti-TNF agents in patients with CD.[14] However, the global prevalence of smok-
ing associated with IBD have not been collated and reported. We conducted a systematic
review to assess the prevalence of smoking in all population based IBD inception cohort stud-
ies. We examined smoking prevalence specific to individual IBD cohorts across time and
geography.
Materials and methods
Search strategy and selection criteria
This systematic review was conducted according to the Meta-analysis of Observational Studies
in Epidemiology (MOOSE) guidelines.[15] A systematic literature search (S1 Table) was con-
ducted on Medline (01 January 1946 to April 5th 2018) and Embase (01 January 1947 to April
5th 2018) for studies assessing the prevalence of smoking at diagnosis in inception IBD
cohorts. All studies from our previous systematic review on IBD epidemiology[1],[5] as well as
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the reference lists of all relevant articles were included. We also obtained data outside of the
search strategy using expert knowledge of active studies as with the Asia-Pacific Crohn’s and
Colitis Epidemiologic Study Group [ACCESS]).
All stages of the systematic review were independently conducted by two teams; the first
from the United Kingdom (TT and JSC) and the second from Hong Kong (SCN, VSWL and
CYL). The first stage consisted of an initial screening of abstracts and titles of search results.
Studies were excluded if they were not observational in design and did not report original data
(i.e. review articles). Studies were considered for final inclusion in the review if their study par-
ticipants consisted of a population-based inception cohort of CD and/or UC with raw numbers
reported to enable the calculation of ever and/or never smoking proportion at time of IBD diag-
nosis. Studies could also be included if they expressed the frequency of smokers or non-smok-
ers. A study was considered to be population-based if the sample was representative of
geographical region. Smoking data had to be reported separately in CD and UC cohorts for
inclusion. Studies that did not report smoking data from time of diagnosis or did not have the
year of IBD diagnosis were excluded. Discrepancies between the reviewers were resolved in con-
junction with GGK, SG and SCN. The flow chart for the above process is presented in Fig 1.
Data analysis
The data extracted included: author, geographical location, study period, size of CD or UC
cohort, frequency of current, former and never-smokers including unknown smoking status.
Study quality was ascertained using a modified version of the Newcastle-Ottawa Scale (S2
Table). The modified scale addressed aspects of quality relevant to population-based inception
cohorts as well as ascertainment of smoking exposure.
We classified geographic regions according to proximity and economic similarity based
upon the United Nations classification of economic region as in our previous work.[1],[5] The
regions included are: North America, South America, Eastern Europe, Northern Europe,
Southern Europe, Western Europe, Asia and Oceania.
Scatter plots (created using Plotly (Montreal, Canada) were used to display time trends
across geography in the proportion of never and ever smokers in inception cohorts of CD (Fig
2) and UC (Fig 3) between 1980 to 2013. The earliest and latest years for which smoking data
was available was 1980 and 2013 respectively. Smoking prevalence in local jurisdictions/regions
were extrapolated to the entire country. In studies that reported smoking prevalence across a
range of years, the median year was selected. Where studies reported former smokers, these
patients were pooled with current smokers to formulate an ever-smoker category. In studies
that reported only current and former category or an ever smoker category, the remainder of
the population were designated as never-smokers. In UC, we sought to assess the former
smoker population as this is considered the at-risk population. However, the former smoker
population was also incorporated into the ever smoker population and reported for consistency.
Studies with a total sample size of less than 10 subjects were excluded from these graphs. Further
analysis in the form of meta-analysis or time trend analyses were not deemed appropriate due
to paucity of data and heterogeneity in study design. Apart from ever smoking and never smok-
ing data, quantitation of smoking in terms of average number of cigarettes smoked or duration
of smoking were not available from the population based epidemiological data.
Results
We identified 41 records from our previous research on IBD inception cohorts1. Our search
strategy identified 3152 additional records from MEDLINE and Embase from January 1948 to
April 31st 2018. Fig 1 demonstrates the number of records eligible for and removed prior to
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full text review. 56 studies were eligible for final inclusion in the systematic review. These
included 44 studies in CD and 46 studies in UC (Fig 1). Characteristics of all included studies
are presented in Tables 1 and 2.
Smoking prevalence figures were reported for: North America (2 studies), South America (1
study), Eastern Europe (3 studies), Northern Europe (16 studies), Southern Europe (12 studies),
Western Europe (4 studies), Asia (15 studies), and Oceania (3 studies). Scatter plots represent-
ing never-smoker prevalence in the CD and UC cohorts from 1980 to 2018 stratified by geo-
graphic region are presented in Figs 2 and 3 respectively. Smoking prevalence varied greatly
according to geographic region. Fig 2 shows that an increasing number of the newly diagnosed
CD population over the last two decades in the West particularly in the UK have never smoked.
In contrast, a decrease in the proportion of never-smokers over the 1990s and 2000s is seen in
newly industrialised nations such as China. Fig 3 is suggestive of significant heterogeneity in the
trend of the never-smoker group in the newly diagnosed UC population in the West. Data from
the United Kingdom and Sweden over the 1980s and 1990s suggest a decrease in this group
whilst data from Iceland and Italy show an increase in the never-smoking proportion. Fig 3
Fig 1. Study selection.
https://doi.org/10.1371/journal.pone.0221961.g001
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Fig 2. The proportion of never smokers at diagnosis in global population based inception cohorts of Crohn’s disease stratified by region, country and year (1946–
2018).
https://doi.org/10.1371/journal.pone.0221961.g002
Fig 3. The proportion of never smokers at diagnosis in global population based inception cohorts of ulcerative colitis stratified by region, country and year (1946–
2018).
https://doi.org/10.1371/journal.pone.0221961.g003
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Table 1. Smoking prevalence in global population-based inception cohorts of Crohn’s disease stratified by region, country and year (1946–2018).
Author Country Area Year Total
CD
(n)
Age
Category
Age; Mean�
(SD),
Median#
(Range)
Ever
Smoker
(n)
Ever
Smoker
(%)
Never
Smoker
(n)
Never
Smoker
(%)
Missing
Data
Defined
smoking
groupsa
Asia (n = 8)
Leong 2004[56] China Hong Kong 1985–2001 80 all ages 33.1 (14)� 20 25 60 75 0 Yes
Lok 2007[30] China Hong Kong 1991–2006 27 all ages 26 (11–56)� 2 7.4 25 92.6 0 Yes
Zhao 2013[57] China Wuhan 2010 34 all ages 36# 22 65 12 35 0 Yes
Zeng 2013[58] China Guangdong 2011–2012 17 all ages 25� 2 11.8 15 88.2 0 Yes
ACCESS Study China Nationwide 2011–2013 142 - - 38 26.8 104 73.2 3.4 Yes
Yang 2014[59] China Daqing 2012–2013 2 all ages 39.5� 2 100 0 0 0 Yes
Zahedi 2014[60] Iran Kerman 2011–2012 6 all ages 33.3� 2 33.3 4 66.6 0 No
Tozun 2009[61] Turkey Nationwide 2001–2003 216 all ages 37.4 (12.8)� 87 40.3 129 59.7 0 Yes
Eastern Europe (n = 3)
Lakatos 2013[8] Hungary Veszprem 1977–2001 506 all ages 31.5 (13.8)� 239 55.7 224 44.3 0 No
Lakatos 2011[28] Hungary Veszprem 2002–2006 163 all ages 32.5 (15.1)� 81 49.8 82 50.2 0 Yes
Gheorghe 2004[62] Romania Nationwide 2002–2003 85 all ages 43.9 (15.6)� 25 29.8 60 71.2 0 Yes
Northern Europe (n = 16)
Ramadas 2010[63] UK Cardiff 1986–1991 105 all ages 30 (4–78)# 52 49 n/a n/a 0 No
Yapp 2000[18] UK Cardiff 1991–1995 84 all ages - 36 43 32 38 19 Yes
Ramadas 2010[63] UK Cardiff 1992–1997 99 all ages 29 (12–73)# 39 39 n/a n/a 0 No
Garcia 2005[64] UK Nationwide 1995–1997 171 20–84 - 79 46.2 74 43.3 10.5 Yes
Tsironi 2004[33] UK Tower
Hamlets
1997–2001 19 all ages 19 (10–75)# 6 31.6 13 68.4 0 No
Ramadas 2010[63] UK Cardiff 1998–2003 137 all ages 31 (7–84)# 57 41 n/a n/a 0 No
Gunesh 2008[65] UK Cardiff 1996–2005 212 all ages 31 (8–87)# 109 51.4 93 43.9 4.7 Yes
Chhaya 2016[19] UK Nationwide 1989–2009 9391 all ages - 2787 29.7 6070 64.6 5.7 Yes
Persson 1990[16] Sweden Stockholm
County
1984–1987 152 >15
years
- 101 66.5 48 31.6 1.97 Yes
Sjoberg 2014[17] Sweden Uppsala 2005–2009 264 all ages 34.8 (19.4)� 81 30.7 113 42.8 26.5 Yes
Kiudelis 2012[66] Lithuania Kaunas 2007–2009 16 all ages 34.94 (10.4)� 6 37.5 10 62.5 0 Yes
Bjornsson 1998[36] Iceland Nationwide 1980–1989 75 all ages 34.4 (4–79)# 18 24 7 9.3 66.7 Yes
Bjornsson 2000[37] Iceland Nationwide 1990–1994 64 all ages 29.7 (9–76)# 20 31.3 27 42.1 26.6 Yes
Bjornsson 2015[67] Iceland Nationwide 1995–2009 279 all ages 38 (3–86)# 76 27.2 n/a n/a 35 No
Hammer 2016[68] Faroe
Islands
Faroe Islands 1960–2014 113 all ages 41� 52 54 43 46 0 Yes
Vind 2006[35] Denmark Copenhagen 2003–2005 209 all ages 31 (10–85)# 108 51.7 92 44 4.3 Yes
Southern Europe (n = 9)
Vucelic 1991[69] Croatia Zagreb 1975–1989 106 all ages - 52 49 n/a n/a n/a No
Manousos 1996b
[70]
Greece Heraklion 1990–1994 37 all ages - 28 76 9 24 0 Yes
Franceschi 1987
[24]
Italy Milan 1983–1984 109 all ages - 82 75.23 17 15.6 0 Yes
Tragnone 1993[40] Italy Bologna 1986–1989 38 >10
years
36.6 (10–
80)�
18 48 20 52 0 Yes
Ranzi 1996[25] Italy Crema and
Cremona
1990–1994 40 all ages - 15 39 23 61 5 Yes
Cottone 2006[71] Italy Casteltermini 1979–2002 29 all ages 29 (17–62)# 20 68.9 9 31 0 Yes
Fraga 1997[39] Spain Barcelona 1997 54 - 37 (14)� 30 55.5 24 44 0 Yes
Rodrigo 2004[27] Spain Oviedo 2000–2002 37 all ages 33 (15)� 17 46 n/a n/a n/a No
(Continued)
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shows that the proportion of people who have never smoked at UC diagnosis in newly industri-
alised nations particularly China has been decreasing over the last two decades. Tables 3 and 4
displays these ranges stratified according to geographic region.
Crohn’s disease
Smoking prevalence data at diagnosis of CD was collected from twenty countries. The western
world particularly Europe has demonstrated an overall increase in the prevalence of never
smokers in the newly diagnosed CD cohort over the last three decades.
In Sweden (Northern Europe), the proportion of never-smokers increased from 31.6%[16]
in the 1980s to 42.8% (2007)[17]. In the early 1990s, the proportion of never-smokers in the
newly diagnosed CD cohort in the UK was 38%.[18] A large population-based inception
cohort study (1989–2009)[19] in the UK estimated that 64.6% of newly diagnosed CD patients
were never-smokers. This trend is replicated in Western Europe, Southern Europe and Eastern
Europe. The proportion of never-smokers in the CD cohort in the Netherlands ranged from
29.7%[20] to 31%[21] in the 1990s however France and Germany demonstrated a never-
smoker proportion of 65%[22] and 63.1%[23] in the 2000s respectively. In Italy (Southern
Europe), there was a steady increase in the never-smoker population at CD diagnosis over the
course of the 1980s[24] and 1990s.[25] Similarly, Spain showed consistent trends with the
ever-smoker group steadily declining from 66%(1980 and 1990s)[26] to 46%(2001)[27] in the
newly-diagnosed CD cohort. Similarly, in Hungary (Eastern Europe), the proportion of never
smokers in the newly diagnosed CD cohort increased from 44.3%[8] to 50.2%[28] over the
course of 30 years.
Table 1. (Continued)
Author Country Area Year Total
CD
(n)
Age
Category
Age; Mean�
(SD),
Median#
(Range)
Ever
Smoker
(n)
Ever
Smoker
(%)
Never
Smoker
(n)
Never
Smoker
(%)
Missing
Data
Defined
smoking
groupsa
Garrido 2004[26] Spain Huelva 1980–2003 30 all ages 32.3 (13–
42)�
10 66.7 n/a n/a n/a No
Western Europe (n = 4)
Abakar-Mahamat
2007[22]
France Corsica 2002–2003 20 all ages 29 (11–58)# 7 35 13 65 0 No
Ott 2008[23] Germany Oberpfalz 2004–2006 168 all ages 28.9 (1–75)# 62 36.9 106 63.1 0 Yes
Van der Heide 2011
[20]
Netherlands Leeuwarden 1996 128 �18
years
30 (23–42)# 90 70.3 38 29.7 0 Yes
Romberg-Camps
2008[21]
Netherlands South
Limburg
1991–2002 476 all ages 34 (5–79)� 328 69 148 31 0 Yes
Oceania (n = 2)
Vegh 2014[44] Australia Melbourne 2011 38 �15
years
37 (17–77)# 13 34.2 20 52.6 13.2 Yes
Niewiadomski 2015
[72]
Australia Victoria 2007–2013 146 all ages 36 (11–82)# 32 22 114 78 0 No
North America (n = 1)
Edwards 2008[73] Barbados Nationwide 1980–2004 47 all ages - 2 4 n/a n/a n/a No
South America (n = 1)
Parente 2015[74] Brazil Piaui 2011–2012 100 �18
years
32.9 (13.6)� 21 21 79 79 0 No
aThe study defined the current smoker and former smoker or never smoker groups. Alternatively, the authors quantified missing data.
https://doi.org/10.1371/journal.pone.0221961.t001
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In contrast to Europe, smoking prevalence in inception CD cohorts in Asia appears to be
increasing over time. The majority of CD subjects in Asia were never-smokers. The proportion
of subjects who had never smoked range from 75%[29] (Hong Kong, China;1985–2001) to
92.6%[30] (Hong Kong, China;1991–2006). However, in a more recent inception cohort from
Asia from 2011-2013(ACCESS), 73.2% of CD subjects were never smokers. Nine out of 44
studies did not report former smokers. Never-smoker populations were assumed to be the
remainder of the population if ever smoker data was provided.
Ulcerative colitis
Smoking prevalence data at diagnosis of UC was collected from twenty-five countries. Smok-
ing trends in Europe for the newly diagnosed UC cohort showed more heterogeneity than in
CD. Data from the United Kingdom appear to suggest a decrease in the never-smoker propor-
tion in the UC cohort during the 1990s; 66.2%(1993)[31] to 58.6%(1995–1997)[32] and 37.5%
(1999)[33]. The former smoker population appears to have decreased in the same decade from
21.6%[31] to 18.8%[33]. Data from Sweden demonstrate reduction in the never smoker popu-
lation from 52.4%(1984–1987)[16] to 32.5%(2005–2009)[34]. An increase in the proportion of
former smokers at diagnosis from 17.9%(1984–1987)[16] to 24.7%(2005–2009)[34] was noted.
Other Scandinavian regions such as Denmark showed only a slightly higher proportion of
never smokers in their UC cohorts; 45%(2004)[35]. In contrast to the remainder of Northern
Europe in the 1980s and 1990s, Iceland demonstrated an increase in the never-smoker propor-
tion from 13.5%[36] to 35.8%[37] across this period. The percentage of former smokers at UC
Table 3. Prevalence of never-smokers in global population-based inception cohorts of Crohn’s disease and ulcerative colitis stratified by range and region (1946–
2018).
Crohn’s disease Ulcerative colitis
Region Lowest estimate Highest estimate Lowest estimate Highest estimate
North America n/a n/a n/a 91.3% (n = 848)
1987–2006;
Mexico City, Mexico
South America n/a 79% (n = 100)
2011–2012;
Piaui, Brazil
n/a 78.9% (n = 152)
2011–2012;
Piaui, Brazil
Eastern Europe 44.3% (n = 506)
1977–2001;
Veszprem, Hungary
71.20% (n = 85)
2002–2003;
Nationwide, Romania
65.5% (n = 220)
2002–2006;
Veszprem, Hungary
86.7% (n = 163)
2002–2003;
Nationwide, Romania
Northern Europe 9.3% (n = 75)
1980–1989;
Nationwide, Iceland
68.4% (n = 19)
1997–2001;
Tower Hamlets London, United Kingdom
13.5% (n = 282)
1980–1989;
Nationwide, Iceland
66.2% (n = 74)
1991–1994;
Leicester, United Kingdom
Southern Europe 15.6% (n = 109)
1983–1984;
Milan, Italy
61% (n = 40)
1990–1994;
Crema and Cremona, Italy
33% (n = 73)
1986–1989;
Bologna, Italy
69.5% (n = 265)
1975–1989;
Zagreb, Croatia
Western Europe 29.7% (n = 128)
1996;
Leeuwarden, Netherlands
65% (n = 20)
2002–2003;
Corsica, France
36% (n = 630)
1991–2002;
South Limburg, Netherlands
77.6% (n = 49)
2002–2003;
Corsica, France
Asia 35% (n = 34)
2010;
Wuhan, China
92.6% (n = 27)
1991–2006;
Hong Kong, China
46.9% (n = 49)
1998–2002;
Trakya, Turkey
91% (n = 23)
2011–2013; Hyderabad, India, India
Oceania 52.6% (n = 38)
2011;
Melbourne, Australia
78% (n = 32)
2007–2013;
Victoria, Australia
29.6% (n = 27)
2011;
Melbourne, Australia
77% (n = 96)
2007–2013;
Victoria, Australia
N: total cohort size; n/a: not available; Studies with n<10 have been excluded.
https://doi.org/10.1371/journal.pone.0221961.t003
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diagnosis also rose from 11.7% to 20% across those two decades. These results co-relate with a
decrease in the ever-smoker proportion down to 48%[38] in the 21st century.
In Southern Europe, Spain demonstrated an increase in their ever-smoker proportion from
12.5%[26] in the 1980s and 1990s to 48%[39] in the 2000s. In Italy, the never-smoker propor-
tion varied by geographic region; 42% (Milan; early 1980s)[24] to 33% (Bologna; late 1980s)
[40] and 44% (Crema and Cremona; early 1990s)[25]. Former-smoker proportions were simi-
larly varied across these regions and time periods: 37.1%, 43% and 39% respectively. In Eastern
Europe, Veszprem (Hungary) demonstrated a reduction in the never-smoker population in
the UC cohort; 67.5%(1977–2008)[8] to 65.5%(2002–2006)[28]. The former smoker popula-
tion in the newly diagnosed UC cohort during those periods were 17.6% and 20.9% respec-
tively. In contrast to the rest of Europe, never-smoker proportions increased over the late
1990s and early 2000s in Western Europe from 44.3%[20] (Netherlands; 1996) to 77.55%
(France; 2003)[22] and 58.09%(Germany;2005)[23].
The proportion of newly diagnosed UC subjects who have never smoked has decreased in
China over the last two decades. The proportion who had never smoked were 84.9%[41] in
China in the late 1990s. By 2012 these figures had decreased to 69.5% (ACCESS Cohort;2011–
2013). The proportion of former smoker patients in the newly diagnosed UC cohort in China
appears to be increasing from 11%(1990–2006)[42] to 34% (Hong Kong ACCESS cohort).
Data from major cities in Australia suggest that the proportion of never-smokers in the
newly diagnosed UC cohort has increased from 58.8%(Sydney;1992)[43] to 77%(Victoria;
2007–2013)[44]. The former smoker proportion of patients at diagnosis also decreased from
Table 4. Prevalence of ever-smokers in global population-based inception cohorts of Crohn’s disease and ulcerative colitis stratified by range and region (1946–
2018).
Crohn’s disease Ulcerative colitis
Region Lowest estimate Highest estimate Lowest estimate Highest estimate
North America n/a 4% (n = 47)
1980–2004;
Barbados, Nationwide
n/a 8.6% (n = 848)
1987–2006;
Mexico City, Mexico
South America n/a 21% (n = 100)
2011–2012;
Piaui, Brazil
n/a 21.1% (n = 152)
2011–2012;
Piaui, Brazil
Eastern Europe 29.8% (n = 85)
2002–2003;
Nationwide, Romania
55.7% (n = 506)
1977–2001;
Veszprem, Hungary
13.3% (n = 163)
2002–2003;
Nationwide, Romania
34.5% (n = 220)
2002–2006;
Veszprem, Hungary
Northern Europe 24% (n = 75)
1980–1989;
Nationwide, Iceland
66.5% (n = 152)
1984–1987;
Stockholm County, Sweden
5.4% (n = 884)
1995–2009;
Nationwide, Iceland
62.5% (n = 16)
1997–2001;
Tower Hamlets, United Kingdom
Southern Europe 39% (n = 40)
1990–1994;
Crema and Cremona, Italy
76% (n = 37)
1990–1994;
Heraklion, Greece
12.5% (n = 40)
1980–2003;
Huelva, Spain
68% (n = 73)
1986–1989;
Barcelona, Spain
Western Europe 35% (n = 20)
2002–2003;
Corsica, France
70.3% (n = 128)
1996;
Leeuwarden, Netherlands
22.5% (n = 49)
2002–2003;
Corsica, France
64% (n = 630)
1991–2002;
South Limburg, Netherlands
Asia 7.4% (n = 27)
1991–2006;
Hong Kong, China
65% (n = 34)
2010;
Wuhan, Turkey
8.70% (n = 23)
2012; Hyderabad, India
53% (n = 49)
1998–2002;
Trakya, Turkey
Oceania 22% (n = 146)
2007–2013;
Victoria, Australia
34.2% (n = 38)
2011;
Melbourne, Australia
23% (n = 96)
2007–2013;
Victoria, Australia
41.2% (n = 102)
1990–1993;
(Sydney, Australia)
N: total cohort size; n/a: not available; Studies with n<10 have been excluded.
https://doi.org/10.1371/journal.pone.0221961.t004
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29.4% to 18% across the same regions and time periods respectively. The impact of missing
smoking data regarding the participants vary due to heterogeneity in reporting. Four out of the
46 studies included for UC did not report former smokers at diagnosis. Never-smoker popula-
tions were assumed to be the remainder of the population if ever smoker data was provided.
Discussion
We present a comprehensive review of smoking trends over time in inception IBD cohorts
worldwide. In the West, the proportion of newly diagnosed CD subjects who have never
smoked has increased over time. The proportion of newly diagnosed UC subjects who have
never smoked has declined in the 1980s and 1990s in Europe although an increase was noted
in Western Europe from the late 1990s. In contrast, the proportion of subjects who have never
smoked at IBD diagnosis has decreased in Asia, particularly in China. Thus, we demonstrate
that trends in smoking prevalence specific to the IBD cohort do not mirror global trends in
smoking discerned from the general population.[45]
The incidence of IBD in newly industrialised countries is accelerating whilst the incidence
of IBD is stabilising in the West.[1] The effect of smoking on the incidence of IBD across the
globe likely varies due to heterogeneity in genetic susceptibility and the presence of other risk
factors. Public health measures in the 1980s and 1990s led to a reduction of smoking preva-
lence in the general population in many Western countries.[46] The higher proportion of
never smokers at diagnosis of CD over time may be explained by adolescents who decided not
to smoke in the 1990s. This could have potentially contributed to the stabilization, and in cer-
tain regions decrease, in the incidence of adult-onset CD in some Western countries. This eco-
logical trend could also explain the decrease in the former smoker population in the UK over
the 1990s and could have contributed to the recent stabilisation of UC incidence.[1]
In contrast, we are at the infancy of the IBD ‘epidemic’ in newly industrialized countries in
Asia, especially in areas of high smoking prevalence[46]; hence ever-smoker trends at IBD diag-
nosis are on the increase. The rapid expansion of the former smoker population at UC diagnosis
in China is suggestive of a rapid expansion of the at-risk population. The Global Burden of Dis-
ease Study 2015 identified China as one of the leading countries in the world for the total num-
ber of smokers.[46] In line with the Lopez model[47], these newly industrialised nations are
rapidly moving towards Stage IV where smoking prevalence in the general population will
decrease as societal attitudes shift and government anti-smoking policy becomes comprehen-
sive. This could potentially foreshadow a protracted course of high UC incidence in comparison
to CD. Similar to the West, we hypothesise that a ‘lag effect’ can be expected in future epidemio-
logical studies particularly in CD based in newly industrialised nations. However, due to the
complex interplay between genetics and environment in the development of IBD, this effect
may not be as pronounced as in the West[12] although in contrast to CD, there is some evi-
dence to suggest that the role of smoking in UC is uniform across the East and West.[12,48,49]
The concurrent decrease of the never-smoker population in both CD and UC cohorts in
newly industrialised nations is potentially suggestive of significant heterogeneity in the interac-
tion between smoking and the process of IBD development across geographic regions. Even in
the West, the incidence of CD had been high in relatively low smoking prevalence populations
i.e. Israeli Jews[50], Canada, and Sweden. Multiple studies[12],[29],[51] in the Asia-Pacific
region have demonstrated that active smoking does not confer an increased risk of CD in this
population as it does in the West. The relative absence of the NOD-2 mutation in CD cases in
Japan suggests that the role of smoking in IBD is subject to underlying genetic heterogeneity.
[52] Environmental factors such as air pollution[53], diet and a Western lifestyle as demon-
strated in migrant sub-populations[6] as well as evolving early life feeding patterns and
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improved hygiene as part of socioeconomic development[12] could be more potent mediators
of IBD development.[54,55]
Our study has several limitations predominantly due to lack of available data. We were
unable to perform a meta-analysis or ecological trend analysis due to study heterogeneity.
Small sample sizes in some studies have also increased the risk of imprecise estimates for
smoking prevalence. A paucity of gender-specific, age-category specific smoking prevalence
data, data relating to quantification of smoking habits or breakdown of rural vs. urban data in
the IBD cohort did not allow for further sub-group analysis. Although, it is possible studies
that included children and adolescents would have a higher prevalence of never-smokers, sum-
mary statistics from included studies suggest this is not the case. The exposure to smoking was
reported inconsistently; some studies reported current and former smokers whilst others
reported ever and never smokers. Twenty three out of ninety-five included cohorts reported
missing smoking data on participants (Tables 1 and 2). No data was available regarding sec-
ond-hand smoking exposure. Due to differing study periods and the generalisation of regions
to represent countries, smoking data was not fully homogenous. The inequalities in healthcare
access across the globe can also affect data collection and reporting. In addition, we acknowl-
edge that the attributable risk of smoking on IBD is low (i.e. most IBD patients do not have a
history of smoking [current or former] prior to their diagnosis), however it remains an impor-
tant risk mediator in the development of IBD.
Despite these limitations, this study provides a comprehensive overview of the prevalence
of smoking in the global IBD cohort across time and geography. The proportion of never-
smokers in IBD cohorts from newly industrialised countries appears to be decreasing over
time in contrast to the IBD cohorts in the West. In light of our previous work and this study, it
appears that IBD epidemiological patterns globally can be modelled along geographical and
development lines within a context of genetic heterogeneity and environmental ecological
exposures. It remains of clinical importance for medical practitioners to record information
and act on smoking status for patients with IBD regardless of geography and ethnicity, espe-
cially in light of data suggesting smoking confers an adverse disease course in CD and is a risk
factor in non-response to anti-TNF therapy.[14] Large-scale prospective inception cohorts
assessing the associations of smoking for both UC and CD in Eastern and Western populations
will add to the available data.
This is the first systematic review to assess trends in the prevalence of smoking in the IBD
cohort worldwide. It provides a foundation for future work assessing the prevalence of this
important risk mediator in a global setting as well as highlighting some of the challenges sur-
rounding this data. A deeper understanding of IBD aetiology in relation to diet and other envi-
ronmental factors across geographic regions and ethnicities is urgently required in order to
formulate strategies to slow the global increase in the incidence of IBD.
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